Neratinib Approved by FDA for HER2-Positive Breast Cancer

FDA has approved neratinib for patients with early-stage HER2-positive breast cancer who have finished at least 1 year of adjuvant therapy with trastuzumab.

Cancer Currents: An NCI Cancer Research Blog